Dr. Hamid on the Evolving Treatment of Immunotherapy in Patients With Solid Tumors

Omid Hamid, MD, director, Melanoma Program, Cedars-Sinai Medical Center, chief, Translational Research and Immunotherapy, director, Melanoma Therapeutics, Phase I Immuno-Oncology Program, The Angeles Clinic and Research Institute, discusses the evolving treatment of immunotherapy in patients with solid tumors.

Immunotherapy options for the treatment of solid tumors has expanded beyond checkpoint inhibitors alone, Hamid says. Adoptive T-cell regimens and T-cell redirector therapeutics have expanded the toolbox of immunotherapy options, Hamid explains.

Along with establishing a foothold in the treatment landscape, novel regimens also present the opportunity to investigate combination therapies, Hamid continues. This gives investigators hope of solving issues currently associated with primary refractoriness and low response rates, Hamid concludes.